These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19158168)

  • 21. Only one of four patients with familial hypercholesterolaemia reach cholesterol treatment goals in primary prevention.
    Hollman G; Ek AC; Olsson AG
    J Intern Med; 2004 Aug; 256(2):176-7. PubMed ID: 15257732
    [No Abstract]   [Full Text] [Related]  

  • 22. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe.
    Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR
    Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996
    [No Abstract]   [Full Text] [Related]  

  • 23. Statins and new-onset diabetes mellitus - a risk lacking in familial hypercholesterolaemia.
    Vuorio A; Strandberg TE; Schneider WJ; Kovanen PT
    J Intern Med; 2016 Apr; 279(4):358-61. PubMed ID: 26260225
    [No Abstract]   [Full Text] [Related]  

  • 24. Diabetes, statins and FH.
    Fuentes F; Alcalá-Díaz JF; Watts GF; Mata P
    Int J Cardiol; 2016 Jan; 203():575. PubMed ID: 26569367
    [No Abstract]   [Full Text] [Related]  

  • 25. Diagnosis and treatment of familial hypercholesterolemia: The impact of recent guidelines.
    Palma L; Welding M; OʼShea J
    Nurse Pract; 2016 Aug; 41(8):36-43. PubMed ID: 27414814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Katsiki N; Athyros VG; Karagiannis A; Mikhailidis DP
    Int Angiol; 2011 Jun; 30(3):295; author reply 296. PubMed ID: 21617615
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Ito MK; McGowan MP; Moriarty PM;
    J Clin Lipidol; 2011 Jun; 5(3 Suppl):S38-45. PubMed ID: 21600528
    [No Abstract]   [Full Text] [Related]  

  • 28. Statins and bone turnover.
    Lips P
    Eur J Clin Invest; 2002 Aug; 32(8):543-4. PubMed ID: 12190951
    [No Abstract]   [Full Text] [Related]  

  • 29. Heterozygous familial hypercholesterolemia: a new point-mutation (1372del2) in the LDL-receptor gene which causes severe hypercholesterolemia.
    Widhalm K; Iro C; Lindemayr A; Schmidt H; Kostner G
    Hum Mutat; 1999 Oct; 14(4):357. PubMed ID: 10502834
    [No Abstract]   [Full Text] [Related]  

  • 30. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Chik G
    Int J Clin Pract; 2001 Dec; 55(10):673-5. PubMed ID: 11777291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A boy with autosomal recessive hypercholesterolaemia.
    Rodenburg J; Wiegman A; Vissers MN; Kastelein JJ; Stalenhoef AF
    Neth J Med; 2004 Mar; 62(3):89-93. PubMed ID: 15209474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia.
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Pharm Des; 2018; 24(31):3597-3598. PubMed ID: 30642238
    [No Abstract]   [Full Text] [Related]  

  • 34. In brief: Zetia and Vytorin: the ENHANCE study.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
    [No Abstract]   [Full Text] [Related]  

  • 35. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia.
    Nozue T; Nohara A; Higashikata T; Inazu A; Mabuchi H; Kajinami K; Koizumi J
    Atherosclerosis; 2000 Dec; 153(2):525-6. PubMed ID: 11187857
    [No Abstract]   [Full Text] [Related]  

  • 37. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 38. Heterozygous familial hypercholesterolemia case study.
    Friedrich DA
    J Am Acad Nurse Pract; 2010 Oct; 22(10):523-6. PubMed ID: 21040085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Management in familial hypercholesterolaemia in children and adolescents. Position of the Lipid Expert Forum].
    Myśliwiec M; Walczak M; Małecka-Tendera E; Dobrzańska A; Cybulska B; Filipiak KJ; Mazur A; Jarosz-Chobot P; Szadkowska A; Rynkiewicz A; Chybicka A; Socha P; Brandt A; Kubalska J; Bautembach-Minkowska J; Limon J; Zdrojewski T; Limon J; Banach M;
    Kardiol Pol; 2013; 71(10):1099-105. PubMed ID: 24197602
    [No Abstract]   [Full Text] [Related]  

  • 40. Could familial hypercholesterolemia oppose the diabetogenic effect of statin? Comments on a new SAFEHEART study.
    Yu Q; Su X; Liu E
    Int J Cardiol; 2016 Jan; 202():954-5. PubMed ID: 26549563
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.